Generated by AI
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapies for serious diseases. Using a proprietary peptide technology platform, the company advances drug candidates designed to address unmet needs in inflammation and immunology, hematology, and metabolic disease. Its current programs center on differentiated medicines such as rusfertide and oral peptide candidates developed for immune-mediated and blood disorders, reflecting a strategy built around targeted mechanisms and convenient routes of administration. Protagonist Therapeutics works across research, clinical development, and collaboration-based programs to create therapies with potential use in conditions where existing treatment options are limited or inadequate. Headquartered in Newark, California, Protagonist Therapeutics plays a specialized role in the biopharmaceutical market by focusing on peptide innovation and translational medicine.
Website7707 Gateway Boulevard
Newark, CA, 94560
United States
The latest articles about PTGX.
Summary of Mar 28's posts. Generated by AI.
Summary of Oct 10's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Summary of Apr 26's posts. Generated by AI.
Investors talking about PTGX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.